Product Details

ADVANCED FIBROMYALGIA SUPPORT

  • image description
  • image description
  • image description

Your Comprehensive Fibromyalgia Solution

  • Contains the 3 most effective ingredients for relief of fibromyalgia symptoms
  • Relieves pain and fatigue
  • Supports mood balance and improves sleep quality
  • Provides high doses for maximum effect

 

Use this product for:

The term “fibromyalgia” refers to a highly debilitating condition that causes widespread pain and tenderness and a decreased quality of life. The primary symptom of fibromyalgia is muscle pain, although it is often accompanied by fatigue, mood changes, sleep difficulties, irritable bowel syndrome, and memory problems. Since the medical establishment has not yet discovered an effective treatment for fibromyalgia, conventional approaches typically involve treating the pain and other symptoms, however this does not address the underlying imbalances at the cellular level. Even though the cause of fibromyalgia is unclear, several nutrients have shown good success in improving quality of life for people with this condition.

Advanced Fibromyalgia Support is the first fibromyalgia product to provide high doses of the three most effective and well-researched natural ingredients shown to help reduce the symptoms of fibromyalgia: D-ribose, magnesium malate and 5-HTP. The evidence shows that after taking 5-HTP, a natural serotonin precursor, fibromyalgia sufferers report better mood, better sleep and less pain. Magnesium malate, a specific form of magnesium, has been shown to improve muscle pain, cramps and brain fog. Both parts of the molecule, magnesium and malate (malic acid), help support the production of energy inside each cell. D-ribose increases energy, reduces post-exercise pain, brain fog and fatigue, and improves sleep. People taking D-Ribose have also reported fewer knots and trigger points in their muscles. 

Advanced Fibromyalgia Support is the most comprehensive natural product available for relief of fibromyalgia symptoms. The added bonus is that Advanced Fibromyalgia Support is delivered in powder form, making it more convenient and economical to get effective doses of each ingredient than taking multiple capsules of 3 separate products.

 

Related products you may be interested in

Discussion

Advanced Fibromyalgia Support™ helps relieve symptoms of fibromyalgia, promotes healthy mood balance, and helps reduce the severity and duration of migraine headaches when taken as a prophylactic. Advanced Fibromyalgia Support™ also contains carbohydrates to support energy production, endurance and performance during extended, high intensity exercise.

Product Variations

NPN Product Code Size
80050889 AOR04337 630 g POWDER

Supplement Facts

Amount Per Serving Amount: 3 Scoops (21 g)
15 g D-Ribose
500 mg Magnesium (malate)
  • 3.5 gMalic acid
  • 300 mg L-5-HTP (from Griffonia simplicifolia seed)
    Non-medicinal ingredients: citric acid.

    AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, corn, nuts, peanuts, sesame seeds, sulphites, mustard, soy, dairy, eggs, fish, shellfish or any animal byproduct.

    Suggested Use:

    (Adult): Take 3 scoops daily with food, or as directed by a qualified health care practitioner. Mix product well in 1-2 cups of liquid (water, juice, etc.) immediately before consumption. To minimize the risk of gastrointestinal side effects, start with ½-1 scoop two to three times per day and slowly increase to effective dose over a 2 week period. Use for a minimum of 1 week to see beneficial effects in mood balance, 2 weeks for relief of fibromyalgia symptoms, and 2-3 weeks for migraine prophylaxis. Ensure to adequately hydrate before, during, and after exercise. Consult a health care practitioner for use beyond one year.

    Cautions :

    Do not use if you have scleroderma. Consult a health care practitioner prior to use if you are pregnant or breastfeeding, taking carbidopa or drugs/supplements with serotonergic activity including but not limited to L-tryptophan, S-adenosylmethionine (SAMe), St. John's wort, antidepressants, pain killers, over the counter cough and cold medication containing dextromethorphan, anti-nausea medication and anti-migraine medication, or if symptoms persist or worsen with use. Discontinue use and consult a health care practitioner if you show signs of weakness, oral ulcers, or abdominal pain accompanied by severe muscle pain or if you experience skin changes. Some people may experience drowsiness. Exercise caution if operating heavy machinery, driving a motor vehicle or involved in activities requiring mental alertness. Some people may experience diarrhea, nausea, vomiting and abdominal pain. Consult a health care practitioner for use beyond 1 year.

    Pregnancy/Breastfeeding :

    Source:

    • 5-HTP - Griffonia simplicifolia seed extract
    • Pharmaceutical synthesis

    Main Applications:

    • Fibromyalgia
    • Energy/Fatigue
    • Pain
    • Mood

    The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.

    The primary symptom of fibromyalgia is muscle pain, although it is often accompanied by fatigue, mood changes, sleep difficulties and memory problems. The cause is often unclear, but several nutrients have shown good success in improving its symptoms. Advanced Fibromyalgia Support is the first fibromyalgia product to provide high doses of several of the most effective and commonly used supplements to help reduce the symptoms of fibromyalgia, including d-ribose, magnesium malate and 5-HTP. Advanced Fibromyalgia Support is in powder form, making it easier to get effective doses of each ingredient.  

    Advanced Fibromyalgia Support is designed to improve quality of life by reducing muscle pain, improving mood and sleep, and increasing energy.  The compound found most effective and best tolerated is 5-HTP. With 5-HTP, people have reported better mood, better sleep and less pain with 100-300 mg a day. Magnesium reduces muscle pain, cramps and brain fog, and helps with sleep, while malic acid improves energy production. D-Ribose increases energy, reduces post-exercise pain, reduces brain fog and fatigue, and improves sleep. People have also reported fewer knots and trigger points in their muscles.

     

    Many types of medications are used to treat the symptoms of fibromyalgia including antidepressants, anticonvulsants, narcolepsy drugs, pain relievers and sleep aids; when used to treat fibromyalgia symptoms, these medications alter brain chemistry to help reduce pain, improve sleep, and ease anxiety or depression. Many of these medications have undesirable side effects, especially when a cocktail is being used, which is often the case. Fibromyalgia is a strange condition for which the cause is difficult to isolate, and treatments are often ineffective or only partially effective. Many supplements have been touted for fibromyalgia, but some are more effective than others.

    This is the first product to combine three of the most effective, well-tolerated and commonly used supplements to reduce the symptoms of fibromyalgia. Advanced Fibromyalgia Support is designed to help those suffering with fibromyalgia lead a more normal, quality lifestyle by reducing pain, improving mood and increasing energy.

    Low Magnesium Levels Contribute to Symptoms of Fibromyalgia

    Fibromyalgia patients often show normal calcium and magnesium serum levels. However, researchers were convinced that magnesium was somehow involved in fibromyalgia. Several studies have now investigated magnesium content in various cells rather than in the blood since very little magnesium is found in the blood in the first place, but is stored in tissues such as bone (therefore, blood tests are not an accurate measure).One study showed high intracellular calcium and low intracellular magnesium in fibromyalgia patients. A hair mineral analysis of fibromyalgia patients showed low magnesium levels, while a serum test did not.

    In an exercise-based study, fibromyalgia patients had lower free magnesium, magnesium-ATP and total ATP during knee extension endurance exercise than controls. This correlated with increased muscle weakness, which is characteristic of fibromyalgia patients. 

    A study investigating the relationship between magnesium levels and fibromyalgia symptoms used magnesium citrate treatment for the relief of symptoms. The study involved 60 pre-menopausal women diagnosed with fibromyalgia, and 20 healthy pre-menopausal women matched for age and weight. The fibromyalgia patients were divided into three groups. The magnesium citrate (300 mg/day) was given to the first group, amitriptyline (10 mg/day) (a tricyclic antidepressant, the most commonly prescribed medication for fibromyalgia) was given to the second group, and magnesium citrate (300 mg/day) amitriptyline (10 mg/day) treatment was given to the third group for 8 weeks. The serum and erythrocyte magnesium levels were significantly lower in patients with fibromyalgia than in the controls. Also there was a negative correlation between the magnesium levels and fibromyalgia symptoms. The number of tender points, tender point index, the Fibromyalgia Impact Questionnaire and (Beck) depression scores decreased significantly with the magnesium citrate treatment. The combined amitriptyline magnesium citrate treatment proved effective on all parameters except numbness. The study concluded that low magnesium levels in the erythrocyte might be a factor in the development of fibromyalgia symptoms.

    Magnesium Malate for Fibromyalgia Symptoms

    In a randomized, placebo-controlled study in twenty-four patients with primary fibromyalgia, 3 tablets twice a day of Super Malic were administered for 4 weeks, followed by a 6-month, open study where the dose was gradually increased up to 6 tablets twice daily. Each tablet contained 200 mg of malic acid and 50 mg of magnesium. During the 6-month follow up, significant reductions in the severity of all 3 primary pain/tenderness measures were obtained without limiting risks.

    D-Ribose for Increasing Energy Levels and Improving Fibromyalgia

    41 patients with a diagnosis of fibromyalgia and/or Chronic Fatigue Syndrome were given D-ribose, a naturally occurring pentose carbohydrate, at a dose of 5 g three times a day for a total of 280 g. D-ribose, which was well-tolerated, resulted in a significant improvement in all five visual analog scale (VAS) categories: energy, sleep, mental clarity, pain intensity, and well-being, as well as an improvement in patients’ global assessment. Approximately 66% of patients experienced significant improvement while on D-ribose, with an average increase in energy on the VAS of 45% and an average improvement in overall well-being of 30%. D-ribose significantly reduced clinical symptoms in patients suffering from fibromyalgia and chronic fatigue syndrome.

    5-HTP Provides Significant Clinical Improvements

    A double-blind, placebo-controlled study of the benefits and tolerability of 5-hydroxytryptophan (5-HTP) was conducted in 50 patients with primary fibromyalgia syndrome in an open 90-day study. All of the clinical parameters studied were significantly improved by treatment with 5-HTP with minimal side-effects reported. The overall evaluation of the patient condition assessed by the patient and the investigator indicated a ‘good’ or ‘fair’ clinical improvement in nearly 50% of the patients during the treatment period. Clinical variables studied throughout the trial included number of tender points, anxiety, pain intensity, quality of sleep and fatigue. The study concluded that 5-HTP is effective in improving the symptoms of primary fibromyalgia syndrome and that it maintains its efficacy throughout the 90-day period of treatment.

    Evidence from multiple studies support the idea of decreased activity through the serotonin pathway in fibromyalgia patients. Serotonin supplementation, by using L-tryptophan or 5-hydroxytryptophan (5-HTP), has been shown to improve symptoms of depression, anxiety, insomnia and somatic pains in a variety of patients. Identification of low serum tryptophan and serotonin levels may be a practical method to identify persons who will respond well to this approach. 5-HTP is well absorbed from an oral dose, with about 70 percent ending up in the bloodstream. It easily crosses the blood-brain barrier and effectively increases central nervous system (CNS) synthesis of serotonin. In the CNS, serotonin levels have been implicated in the regulation of sleep, mood, aggression, appetite, temperature, sexual behaviour, and pain sensation. Therapeutic administration of 5-HTP has been shown effective in treating a wide variety of conditions, including mood imbalances, fibromyalgia, binge eating associated with weight gain, chronic headaches, and insomnia.

     

    Abraham GE, Flechas JD. Management of Fibromyalgia: Rationale for the Use of Magnesium and Malic Acid. Journal of Nutritional and Environmental Medicine 1992, Vol. 3, No. 1 , Pages 49-59.

    Bagis S, Karabiber M, As I, Tamer L, Erdogan C, Atalay A. Is magnesium citrate treatment effective on pain, clinical parameters and functional status in patients with fibromyalgia? Rheumatol Int. 2013 Jan;33(1):167-72.

    Caruso I, Sarzi Puttini P, Cazzola M, Azzolini V. Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res. 1990 May-Jun;18(3):201-9.

    Kim YS, Kim KM, Lee DJ, Kim BT, Park SB, Cho DY, Suh CH, Kim HA, Park RW, Joo NS. Women with fibromyalgia have lower levels of calcium, magnesium, iron and manganese in hair mineral analysis. J Korean Med Sci. 2011 Oct;26(10):1253-7.

    Sakarya ST, Akyol Y, Bedir A, Canturk F. The relationship between serum antioxidant vitamins, magnesium levels, and clinical parameters in patients with primary fibromyalgia syndrome. Clin Rheumatol. 2011 Aug;30(8):1039-43.

    Magaldi M, Moltoni L, Biasi G, Marcolongo R. [Changes in intracellular calcium and magnesium ions in the physiopathology of the fybromyalgia syndrome]. Minerva Med. 2000 Jul-Aug;91(7-8):137-40.

    Neeck G. Neuroendocrine and hormonal perturbations and relations to the serotonergic system in fibromyalgia patients. Scand J Rheumatol Suppl. 2000;113:8-12.

    Nicolodi M, Sicuteri F. Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy. Adv Exp Med Biol. 1996;398:373-9.

    Park, J. H., K. J. Niermann, B. N. Carr, and N. J. Olsen. “Abnormalities in magnesium (Mg2 ) and ATP levels in muscle disorders: dermatomyositis and fibromyalgia.” Int Soc Magnetic Resonance Med 7 (1999): 1537.

    Russell IJ, Michalek JE, Flechas JD, Abraham GE. Treatment of fibromyalgia syndrome with Super Malic: a randomized, double blind, placebo controlled, crossover pilot study. J Rheumatol. 1995 May;22(5):953-8.

    Sarzi Puttini P, Caruso I. Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open study. J Int Med Res. 1992 Apr;20(2):182-9.

    Teitelbaum JE, Johnson C, St Cyr J. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. J Altern Complement Med. 2006 Nov;12(9):857-62.

     

    Is magnesium citrate treatment effective on pain, clinical parameters and functional status in patients with fibromyalgia?

    Rheumatol Int. 2013 Jan;33(1):167-72.

    Bagis S, Karabiber M, As I, Tamer L, Erdogan C, Atalay A.

    The aims of this study were to investigate the relationship between magnesium levels and fibromyalgia symptoms and to determine the effect of magnesium citrate treatment on these symptoms. Sixty premenopausal women diagnosed with fibromyalgia according to the ACR criteria and 20 healthy women whose age and weight matched the premenopausal women were evaluated. Pain intensity, pain threshold, the number of tender points, the tender point index, the fibromyalgia impact questionnaire (FIQ), the Beck depression and Beck anxiety scores and patient symptoms were evaluated in all the women. Serum and erythrocyte magnesium levels were also measured. The patients were divided into three groups. The magnesium citrate (300 mg/day) was given to the first group (n = 20), amitriptyline (10 mg/day) was given to the second group (n = 20), and magnesium citrate (300 mg/day) amitriptyline (10 mg/day) treatment was given to the third group (n = 20). All parameters were reevaluated after the 8 weeks of treatment. The serum and erythrocyte magnesium levels were significantly lower in patients with fibromyalgia than in the controls. Also there was a negative correlation between the magnesium levels and fibromyalgia symptoms. The number of tender points, tender point index, FIQ and Beck depression scores decreased significantly with the magnesium citrate treatment. The combined amitriptyline magnesium citrate treatment proved effective on all parameters except numbness. Low magnesium levels in the erythrocyte might be an etiologic factor on fibromyalgia symptoms. The magnesium citrate treatment was only effective tender points and the intensity of fibromyalgia. However, it was effective on all parameters when used in combination with amitriptyline.

     

    The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study.

    J Altern Complement Med. 2006 Nov;12(9):857-62.

    Teitelbaum JE, Johnson C, St Cyr J.

    OBJECTIVES: Fibromyalgia (FMS) and chronic fatigue syndrome (CFS) are debilitating syndromes that are often associated with impaired cellular energy metabolism. As D-ribose has been shown to increase cellular energy synthesis in heart and skeletal muscle, this open-label uncontrolled pilot study was done to evaluate if D-ribose could improve symptoms in fibromyalgia and/or chronic fatigue syndrome patients.

    DESIGN: Forty-one (41) patients with a diagnosis of FMS and/or CFS were given D-ribose, a naturally occurring pentose carbohydrate, at a dose of 5 g t.i.d. for a total of 280 g. All patients completed questionnaires containing discrete visual analog scales and a global assessment pre- and post-D-ribose administration.

    RESULTS: D-ribose, which was well-tolerated, resulted in a significant improvement in all five visual analog scale (VAS) categories: energy; sleep; mental clarity; pain intensity; and well-being, as well as an improvement in patients’ global assessment. Approximately 66% of patients experienced significant improvement while on D-ribose, with an average increase in energy on the VAS of 45% and an average improvement in overall well-being of 30% (p < 0.0001).

    CONCLUSIONS: D-ribose significantly reduced clinical symptoms in patients suffering from fibromyalgia and chronic fatigue syndrome.

     

    Neuroendocrine and hormonal perturbations and relations to the serotonergic system in fibromyalgia patients.

    Scand J Rheumatol Suppl. 2000;113:8-12.

    Neeck G.

    The symptomatology of the fibromyalgia syndrome (FMS) often resembles an alteration in central nervous set points at least in three systems. The patients suffer under chronic pain in the region of the locomotor system, presumably reflecting a disturbed central processing of pain. Anxiety and depression often characterizes the clinical picture. Almost all of the hormonal feedback mechanisms controlled by the hypothalamus are altered. Characteristic for FMS patients are the elevated basal values of ACTH, follicle-stimulating hormone (FSH), and cortisol as well as lowered basal values of insulin-like growth factor 1 (IGF-1, somatomedin C), free triiodothyronine (FT3), and oestrogen. In FMS patients, the systemic administration of the relevant releasing hormones of corticotropin-releasing hormone (CRH), growth hormone-releasing hormone (GHRH), thyreotropin-releasing hormone (TRH), and luteinizing hormone-releasing hormone (LHRH) leads to increased secretion of ACTH and prolactin, whereas the degree to which TSH can be stimulated is reduced. The stimulation of the hypophysis with LHRH in female FMS patients during their follicular phase results in a significantly reduced LH response. All in all, the typical alterations in set points of hormonal regulation that are typical for FMS patients can be explained as a primary stress activation of hypothalamic CRH neurons caused by the chronic pain. In addition to the stimulation of pituitary ACTH secretion, CRH activates somatostatin on the hypothalamic level, which in turn inhibits the release of GH and TSH on the hypophyseal level. The lowered oestrogen levels could be accounted for both via an inhibitory effect of the CRH on the hypothalamic release of LHRH or via a direct CRH-mediated inhibition of the FSH-stimulated oestrogen production in the ovary. Serotonin (5HT), precursors like tryptophan (5HTP), drugs which release 5HT or act directly on 5HT receptors stimulate HPA axis, indicating a stimulatory serotonergic influence on HPA axis function. Therefore activation of the HPA axis may reflect an elevated serotonergic tonus in the central nervous system of FMS patients.

     

    Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy.

    Adv Exp Med Biol. 1996;398:373-9.

    Nicolodi M, Sicuteri F.

    In this study fibromyalgia sufferers were randomly administered a combination of monoamine-oxidase inhibitors (MAOIs)-A/B with 5-HTP, 5-HTP alone, MAOIs-A/B alone, or the tricyclic drug amitriptyline in order to compare the efficacy of these treatments. The benefits on the painful syndrome were assessed by using Visual Analogic Scale score rating from 0 to 4. The combination of MAOIs with 5-HTP significantly improved fibromyalgia syndrome as determined by Visual Analogic Scale whereas the other treatments yielded poorer benefits. No subject withdrew from the trial due to adverse effects, even if some sleep disturbances and mild stomach-ache were reported. The tolerability of the association MAOIs/5-HTP was good, although a transient cheese effect occurred in one of the patients treated with MAOIs as well as in a patient treated with the association MAOIs and 5-HTP. No one of these two cases was due to pharmacological dietetic mistake of the patient. In both the cases the transient hypertension was associated to very dramatic emotional events. The benefits obtained by using the combination of MAOIs with 5-HTP can be explained with a treatment-induced enhancement of aminergic and serotonergic transmission. The recently shown high prevalence of migraine in the population of fibromyalgia sufferers, suggests a common ground shared by fibromyalgia and migraine. Migraine has been demonstrated to be characterized by a defect in the serotonergic and adrenergic systems. A parallel dramatic failure of serotonergic systems and a defect of adrenergic transmission have been evidenced to affect fibromyalgia sufferers too. Enhancing serotonergic analgesia while increasing adrenergically mediated analgesia seems to be an important tool in fibromyalgia. Treatment consisting with the association MAOIs/5-HTP is aimed at enhancing serotonergic/adrenergic transmission by inducing an up-regulation of serotonergic/adrenergic receptors and a simultaneous increase of serotonin levels in the central nervous system.

     

    Treatment of fibromyalgia syndrome with Super Malic: a randomized, double blind, placebo controlled, crossover pilot study.

    Russell IJ, Michalek JE, Flechas JD, Abraham GE.

    J Rheumatol. 1995 May;22(5):953-8.

    OBJECTIVE: To study the efficacy and safety of Super Malic, a proprietary tablet containing malic acid (200 mg) and magnesium (50 mg), in treatment of primary fibromyalgia syndrome (FM).

    METHODS: Twenty-four sequential patients with primary FM were randomized to a fixed dose (3 tablets bid), placebo controlled, 4-week/course, pilot trial followed by a 6-month, open label, dose escalation (up to 6 tablets bid) trial. A 2-week, medication free, washout period was required before receiving treatment, between blinded courses, and again before starting open label treatment. The 3 primary outcome variables were measures of pain and tenderness but functional and psychological measures were also assessed.

    RESULTS: No clear treatment effect attributable to Super Malic was seen in the blinded, fixed low dose trial. With dose escalation and a longer duration of treatment in the open label trial, significant reductions in the severity of all 3 primary pain/tenderness measures were obtained without limiting risks.

    CONCLUSIONS: These data suggest that Super Malic is safe and may be beneficial in the treatment of patients with FM. Future placebo-controlled studies should utilize up to 6 tablets of Super Malic bid and continue therapy for at least 2 months.

     

    Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open study.

    J Int Med Res. 1992 Apr;20(2):182-9.

    Sarzi Puttini P, Caruso I.

    The efficacy and tolerability of 5-hydroxy-L-tryptophan (5-HTP) were studied in an open 90-day study in 50 patients affected by primary fibromyalgia syndrome. When all the clinical variables studied throughout the trial (number of tender points, anxiety, pain intensity, quality of sleep, fatigue) were compared with baseline results, they all showed a significant improvement (P less than 0.001). The overall evaluation of the patient condition assessed by the patient and the investigator indicated a ‘good’ or ‘fair’ clinical improvement in nearly 50% of the patients during the treatment period. A total of 15 (30%) patients reported side-effects but only one patient was withdrawn from the treatment for this reason. No abnormality in the laboratory evaluation was observed. It is concluded that 5-HTP is effective in improving the symptoms of primary fibromyalgia syndrome and that it maintains its efficacy throughout the 90-day period of treatment.

     

    Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome.

    J Int Med Res. 1990 May-Jun;18(3):201-9.

    Caruso I, Sarzi Puttini P, Cazzola M, Azzolini V.

    A double-blind, placebo-controlled study of the efficacy and tolerability of 5-hydroxytryptophan (5-HTP) was conducted in 50 patients with primary fibromyalgia syndrome. All the clinical parameters studied were significantly improved by treatment with 5-HTP and only mild and transient side-effects were reported. Further controlled studies are required to define properly the value of 5-HTP in patients with primary fibromyalgia syndrome.

     

    image description
    image description